• 1.昆明醫(yī)學(xué)院第二附屬醫(yī)院腫瘤科(昆明 650101);;
  • 2.昆明醫(yī)學(xué)院第二附屬醫(yī)院普外科(昆明 650101);

目的  探討促甲狀腺激素(TSH)抑制療法在分化型甲狀腺癌患者術(shù)后治療中的作用。方法  106例分化型甲狀腺癌行全或近全甲狀腺切除術(shù)的患者術(shù)后分別行TSH抑制治療（TSH抑制治療組）或甲狀腺素替代治療（甲狀腺素替代治療組），通過Wilcoxon(Gehan比分)檢驗分析比較2組患者的術(shù)后無復(fù)發(fā)和（或）無轉(zhuǎn)移率。 結(jié)果  TSH抑制治療組3年、5年及10年的無復(fù)發(fā)和（或）無轉(zhuǎn)移率分別為98.31%、92.41%及75.45%，甲狀腺素替代治療組分別為93.57%、84.18%及52.06%，前組明顯高于后組（P=0.046 5）。結(jié)論  TSH抑制療法是分化型甲狀腺癌患者行全或近全甲狀腺切除術(shù)后的有效治療手段。

引用本文： 馬峻峰,唐波,李鐵漢,張捷. 促甲狀腺激素抑制療法在分化型甲狀腺癌治療中的作用. 中國普外基礎(chǔ)與臨床雜志, 2009, 16(5): 348-350. doi: 復(fù)制

1. Williams ED. Mechanisms and pathogenesis of thyroid cancer in animals and man [Ｊ]. Mutat Res, 1995; 333(1-2): 123-129.
2. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma [Ｊ]. Thyroid, 1999; 9(5): 421-427.
3. 鄭澤霖， 蓋寶東， 孫輝. 分化型甲狀腺癌手術(shù)范圍探討 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2004; 11(6): 479-480.
4. Manzone TA, Dam HQ, Intenzo CM, et al. Postoperative management of thyroid carcinoma [Ｊ]. Surg Oncol Clin N Am, 2008; 17(1): 197-218.
5. Sherman SI. Thyroid carcinoma [Ｊ]. Lancet, 2003; 361(9356): 501-511.
6. 薛緒潮， 方國恩. 甲狀腺癌的內(nèi)分泌治療 [Ｊ]. 中國實(shí)用外科雜志， 2004; 24(10): 631-632.
7. Shiba E. Diagnosis and treatment of differentiated thyroid carcinoma [Ｊ]. Nippon Geka Gakkai Zasshi, 2005; 106(8): 459-462.
8. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry [Ｊ]. Thyroid, 1998; 8(9): 737-744.
9. 李小毅. 甲狀腺球蛋白在分化型甲狀腺癌診治中的作用 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2006; 13(3): 265-267.
10. Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls [Ｊ]. Endocrinol Metab Clin North Am, 1995; 24(4): 841-863.
11. Miyakawa M. Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma [Ｊ]. Nippon Rinsho, 2007; 65(11): 2073-2077.
12. Heemstra KA, Hamdy NA, Romijn JA， et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma [Ｊ]. Thyroid, 2006; 16(6): 583-591.
13. Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs [Ｊ]. Drug Saf， 1996; 15(1): 53-63.
  1. 1. Williams ED. Mechanisms and pathogenesis of thyroid cancer in animals and man [Ｊ]. Mutat Res, 1995; 333(1-2): 123-129.
  2. 2. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma [Ｊ]. Thyroid, 1999; 9(5): 421-427.
  3. 3. 鄭澤霖， 蓋寶東， 孫輝. 分化型甲狀腺癌手術(shù)范圍探討 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2004; 11(6): 479-480.
  4. 4. Manzone TA, Dam HQ, Intenzo CM, et al. Postoperative management of thyroid carcinoma [Ｊ]. Surg Oncol Clin N Am, 2008; 17(1): 197-218.
  5. 5. Sherman SI. Thyroid carcinoma [Ｊ]. Lancet, 2003; 361(9356): 501-511.
  6. 6. 薛緒潮， 方國恩. 甲狀腺癌的內(nèi)分泌治療 [Ｊ]. 中國實(shí)用外科雜志， 2004; 24(10): 631-632.
  7. 7. Shiba E. Diagnosis and treatment of differentiated thyroid carcinoma [Ｊ]. Nippon Geka Gakkai Zasshi, 2005; 106(8): 459-462.
  8. 8. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry [Ｊ]. Thyroid, 1998; 8(9): 737-744.
  9. 9. 李小毅. 甲狀腺球蛋白在分化型甲狀腺癌診治中的作用 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2006; 13(3): 265-267.
  10. 10. Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls [Ｊ]. Endocrinol Metab Clin North Am, 1995; 24(4): 841-863.
  11. 11. Miyakawa M. Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma [Ｊ]. Nippon Rinsho, 2007; 65(11): 2073-2077.
  12. 12. Heemstra KA, Hamdy NA, Romijn JA， et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma [Ｊ]. Thyroid, 2006; 16(6): 583-591.
  13. 13. Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs [Ｊ]. Drug Saf， 1996; 15(1): 53-63.